Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

1.66
-0.0800-4.60%
Post-market: 1.680.0200+1.20%19:07 EDT
Volume:1.09M
Turnover:2.05M
Market Cap:22.38M
PE:-0.16
High:1.95
Open:1.94
Low:1.65
Close:1.74
52wk High:12.23
52wk Low:1.65
Shares:13.48M
Float Shares:8.64M
Volume Ratio:3.56
T/O Rate:12.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.1030
EPS(LYR):-19.4955
ROE:-405.03%
ROA:-89.32%
PB:3.53
PE(LYR):-0.09

Loading ...

Tempest Therapeutics CEO and President Matthew Angel acquires 231,482 common shares; value rises to $500,001

Reuters
·
Yesterday

Tempest Therapeutics announces USD 2 million private placement of 925,927 shares

Reuters
·
Mar 23

Tempest Therapeutics Announces up to $6 Million Private Placement

THOMSON REUTERS
·
Mar 23

Press Release: Tempest Therapeutics Announces Up To $6 Million Private Placement

Dow Jones
·
Mar 23

Tempest Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview

Reuters
·
Mar 23

Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support

Reuters
·
Mar 11

Tempest Announces Partnership for Tpst-2003 in Preparation for Planned U.S. Registrational Study in 2026

THOMSON REUTERS
·
Mar 11

Jakarta's Solution to Ease Burden on Bantargebang Landfill

Tempo
·
Mar 11

Bantargebang Landfill Landslide Death Toll Rises to Five

Tempo
·
Mar 10

Bantargebang Landfill Tragedy Shows Waste Management Failure, Minister Says

Tempo
·
Mar 09

3 People Killed in Bekasi's Bantargebang Landfill Landslide

Tempo
·
Mar 08

Tempest reports 100% complete response rate in interim REDEEM-1 trial of TPST-2003 CAR-T therapy

Reuters
·
Feb 25

Tempest Therapeutics Inc - Favorable Safety Profile With No Grade 3 or Higher Crs

THOMSON REUTERS
·
Feb 25

Tempest Therapeutics: Co Also Exploring Potential Development of Tpst-2003 to Include Patients With Lbcl, Other Related Indications

THOMSON REUTERS
·
Feb 25

Tempest Therapeutics Inc - to Initiate U.S. Registrational Study in 2026

THOMSON REUTERS
·
Feb 25

Tempest Therapeutics Inc - 100% Complete Response Rate Among All Six Efficacy Evaluable Patients

THOMSON REUTERS
·
Feb 25

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

GlobeNewswire
·
Feb 25

BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy

Reuters
·
Feb 11

BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs

Reuters
·
Feb 11

Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies

Reuters
·
Feb 11